ADCC is mediated by the binding of therapeutic antibodies to specific antigens expressed on the surface of cancer cells. The Fc region of these antibodies then interacts with Fc receptors (FcγR) on the surface of effector cells. This interaction activates the effector cells, leading to the release of cytotoxic molecules such as perforin and granzymes, which induce apoptosis in the target cancer cells.
